Literature DB >> 23557336

The paradoxical role of Nrf2 in tumor biology.

Hui Shen1, Suna Zhou, Jiansheng Wang.   

Abstract

Nrf2 is used as a cell protector by mediating many downstream genes which express phase II detoxifying and antioxidant enzymes. Recently, large numbers of experiments have shown Nrf2 and its downstream genes are found to be overexpressed in many human tumors. Numerous evidences unveil that Nrf2 protects the normal cells while promoting the malignant tumor's progression. The paradoxical role of Nrf2 has not been clearly elucidated before. Here, we review the suppressor or oncogene roles of Nrf2 in different stages of specific tumors with respect to the newest studies. Further, we suspect that the hypoxic microenvironment around the tumors is the main crux which determines the role of Nrf2 in the tumor initiation, invasion, and metastasis. In the initiation of tumors, Nrf2 or Keap1 genes get mutations under the oxidative stress; as a result, the tumor cells obtain the advantage to growth. At the later stages, the hypoxic microenvironment around the malignant tumors has a profound influence on the character of Nrf2. Under the hypoxic microenvironment, expression of certain downstream genes of Nrf2 involved in angiogenesis are obviously elevated; other transcription factors derived from hypoxic microenvironment interact with Nrf2 and in that way promote or inhibit the invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557336     DOI: 10.1615/critreveukargeneexpr.2013006288

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  9 in total

Review 1.  p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer.

Authors:  Koji Taniguchi; Shinichiro Yamachika; Feng He; Michael Karin
Journal:  FEBS Lett       Date:  2016-08-06       Impact factor: 4.124

Review 2.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

Review 3.  Inflammatory pathways in the early steps of colorectal cancer development.

Authors:  Francesco Mariani; Paola Sena; Luca Roncucci
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome.

Authors:  Vibeke A Ingebrigtsen; Kjetil Boye; Jahn M Nesland; Arild Nesbakken; Kjersti Flatmark; Øystein Fodstad
Journal:  BMC Cancer       Date:  2014-08-20       Impact factor: 4.430

5.  NF-κB and Nrf2 signaling pathways contribute to wogonin-mediated inhibition of inflammation-associated colorectal carcinogenesis.

Authors:  J Yao; L Zhao; Q Zhao; Y Zhao; Y Sun; Y Zhang; H Miao; Q-D You; R Hu; Q-L Guo
Journal:  Cell Death Dis       Date:  2014-06-05       Impact factor: 8.469

6.  Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Authors:  Fengju Chen; Yiqun Zhang; Dominick Bossé; Aly-Khan A Lalani; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Don L Gibbons; Michael Ittmann; Chad J Creighton
Journal:  Nat Commun       Date:  2017-08-04       Impact factor: 14.919

7.  Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients.

Authors:  Andrew Lee; James Pike; Michael R Edwards; Jennifer Petrillo; John Waller; Eddie Jones
Journal:  Neurol Ther       Date:  2017-01-16

8.  Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis.

Authors:  Z Fan; A-K Wirth; D Chen; C J Wruck; M Rauh; M Buchfelder; N Savaskan
Journal:  Oncogenesis       Date:  2017-08-14       Impact factor: 7.485

Review 9.  The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders.

Authors:  Bifeng Gao; An Doan; Brooks M Hybertson
Journal:  Clin Pharmacol       Date:  2014-02-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.